RecruitingNot ApplicableNCT07506369

Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans


Sponsor

University Hospital, Gentofte, Copenhagen

Enrollment

18 participants

Start Date

Apr 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabolism in healthy humans. The aim of this study is to investigate the interaction between the hormones and obtain insight into the physiology of the hormones. The healthy participants will undergo 4 study days in a randomised order receiving the following infusions for 5 hours: A) Amylin + PP B) Amylin + Placebo C) Placebo + PP D) Placebo + Placebo Throughout the day blood samples will be collected and gallbladder motility will be evaluated. Further, indirect calorimetry and heart rate/blood pressure measurement will be performed.


Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Amylin (Pramlintide), a drug called Pancreatic Polypeptide (PP), and others for people with obesity, overweight. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAmylin (Pramlintide)

This a one of the pancreatic hormones investigated in this study. Pramlintide is used a surrogate for amylin due to the fibrillating properties of amylin

DRUGPancreatic Polypeptide (PP)

This a one of the pancreatic hormones investigated in this study.

DRUGPlacebo (NaCl 0.9 % solution)

This the placebo


Locations(1)

Center for Clinical Metabolic Research, Gentofte Hospital

Hellerup, Capital Region, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07506369


Related Trials